Q-omics provides the consensus-scored FAM167A-AS1 profile across patient tissues and cancer cell-line models. FAM167A-AS1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, FAM167A-AS1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, FAM167A-AS1 RNA expression shows 9,782 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THYM, KIRC, and TGCT as cancer lineages where FAM167A-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM167A-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM167A-AS1 survival associations across molecular data types. FAM167A-AS1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM167A-AS1 RNA expression–survival associations across cancer types. High FAM167A-AS1 expression shows unfavorable associations in THYM and KIRC, but favorable associations in MESO, ACC, BLCA and UCS. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for FAM167A-AS1 RNA expression.
This table summarizes FAM167A-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM167A-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM167A-AS1 shows lower tumor expression in KIRC, THCA, KIRP, LUAD, KICH and UCEC. The KIRC box plot shows higher FAM167A-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.513, t-test p < 0.001).
This table shows molecular features associated with FAM167A-AS1 in patient tissues and cancer cell lines. In patient samples, FAM167A-AS1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
